Allergan to acquire Acelity’s regenerative medicine unit LifeCell for $2.9bn
Allergan | December 22, 2016
US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders.